Rocephin

Ceftriaxone disodium

Sepsis; meningitis; early & late stages of disseminated Lyme borreliosis; abdominal infections (peritonitis, biliary & GIT infections); infections of bones, joints, soft tissue, skin & wounds; infections in patients w/ impaired defense mechanisms; renal infections & UTI; resp tract infections, particularly pneumonia & ENT infections; genital infections including gonorrhoea. Perioperative infection prophylaxis.

IM/IV/IV infusion IV administration should be given over 2-4 min. IV infusion should be given over at least 30 min. Adult & childn >12 yr 1-2 g once daily (every 24 hr). Severe cases or infections caused by moderately sensitive organisms 4 g once daily. Childn weighing ≥50 kg Give adult dose. Childn up to 12 yr & infant ≥50 mg/kg by infusion over at least 30 min or 60 min (in neonates). Childn, infant & neonate (15 days to 12 yr) 20-80 mg/kg once daily. Neonate up to 14 days 20-50 mg/kg once daily. Max: 50 mg/kg daily. Meningitis Childn & infant Initially 100 mg/kg (up to max 4 g) once daily. Duration of therapy: Neisseria meningitidis: 4 days, H. influenzae: 6 days, Strep pneumoniae: 7 days. Lyme borreliosis Adult & childn 50 mg/kg to max 2 g once daily for 14 days. Gonorrhoea (penicillinase-producing & nonpenicillinase-producing strains) 250 mg IM as single dose. Perioperative prophylaxis 1-2 g single dose 30-90 min prior to surgery. Preterminal renal failure (CrCl <10 mL/min) Max: 2 g daily.

Hypersensitivity to ceftriaxone or any other cephalosporin, penicillin & other β-lactam agents. Ceftriaxone soln w/ lidocaine should not be administered IV. Co-administration w/ Ca-containing IV soln treatment in neonates ≤28 days. Premature neonates up to postmenstrual age of 41 wk. Hyperbilirubinemic newborns.

History of hypersensitivity to other cephalosporins or any other type of β-lactam agents. Discontinue treatment if severe hypersensitivity reactions; anemia; Ca-ceftriaxone precipitates in gallbladder occur. Immune mediated hemolytic anemia; Clostridium difficile-associated diarrhea (CDAD); pancreatitis. Superinfections may occur. Appropriate fluid & electrolyte management, protein supplementation, antibiotic treatment of C. difficile, & surgical evaluation if CDAD is suspected or confirmed. Perform CBC at regular intervals during prolonged treatment. May falsely lower estimated blood glucose values. Monitor patients w/ both severe renal & hepatic dysfunction for safety & efficacy. Not to be mixed or administered simultaneously w/ Ca-containing soln. False +ve test results for galactosemia & nonenzymatic methods for glucose determination in urine. May influence ability to drive & use machines. Pregnancy & lactation. Not to be used in neonates (especially prematures) at risk of developing bilirubin encephalopathy. Elderly (w/ severe renal & hepatic impairment).

Eosinophilia, leucopenia, thrombocytopenia; diarrhoea, loose stools; increased hepatic enzyme; rash.

Antagonistic effect w/ chloramphenicol. Precipitation of ceftriaxone-Ca w/ Ca-containing soln. Increased risk of bleeding w/ vit K antagonists.

Cephalosporins

J01DD04 - ceftriaxone ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.

S